Relationship between clotting activity and phosphatidylserine expression on erythrocyte membranes in polycythemia vera patients with the JAK2 V617F mutation

References

• Anía B, Suman V, Sobell J, Codd M, Silverstein M, Melton L. (1994). Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am J Hematol 47:89–93.
   PubMed Web of Science ®Google Scholar
• Aucar JA, Isaak E, Anthony D. (2009). The effect of red cell age on coagulation. Am J Surg 198:900–4.
   PubMedGoogle Scholar
• Barbui T, Carobbio A, Rambaldi A, Finazzi G. (2009). Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor? Blood 114:759–63.
   PubMed Web of Science ®Google Scholar
• Betal SG, Setty BN. (2008). Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain. Translational Res 152:165–72.
   PubMed Web of Science ®Google Scholar
• Bonomini M, Sirolli V, Gizzi F, Di Stante S, Grilli A, Felaco M. (2002). Enhanced adherence of human uremic erythrocytes to vascular endothelium: Role of phosphatidylserine exposure. Kid Int 62:1358–63.
   PubMed Web of Science ®Google Scholar
• Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. (1996). Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 52:14–20.
   PubMed Web of Science ®Google Scholar
• Califano F, Glovanniello T, Campana E, Parlapiano C, Alegiani F, Vincentelli GM, Turchetti P. (2000). Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci 4:59–66.
   PubMedGoogle Scholar
• Chiu D, Lubin B, Roelofen B, van Deene LL. (1981). Sickle erythrocytes accelerate clotting in vitro: An effect of abnormal membrane lipid asymmetry. Blood 58:398–401.
   PubMed Web of Science ®Google Scholar
• Deguchi A, Ohnishi K, Nakamura S, Hamaguchi H, Kawamura Y, Murashima S, Shiku H, Tanii Y, Deguchi K. (1997). Plasma thrombomodulin values and hepatorenal function in the elderly. Arch Gerontol Geriat 24:47–54.
   PubMed Web of Science ®Google Scholar
• Fujita H, Sakuma R, Tomiyama J, Hamaki T, Ohwada A, Kurosawa S, Nishimura S. (2011). Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia vera. Br J Haematol 152, 234–6.
   PubMedGoogle Scholar
• Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, Yanagisawa K, Matsuda I, Nakamaki T, Gomi K. et al (2008). Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V167F mutation. Int J Hematol 88:181–8.
   PubMed Web of Science ®Google Scholar
• Hebbel RP. (1991). Beyond hemoglobin polymerization: The red blood cell membrane and sickle disease pathophysiology. Blood 77:214.
   PubMed Web of Science ®Google Scholar
• Holovati JL, Wong KA, Webster JM, Acker JP. (2008). The effects of cryopreservation on red blood cell microvesiculation, phosphatidylserine externalization, and CD47 expression. Transfusion 48:1658–68.
   PubMed Web of Science ®Google Scholar
• Lamparter S, Schuermann M, Heidmann HH. (1997). APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis. Ann Hematol 74:49–50.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Castoldi E, Spronk HMH, van Oerle R, Balducci D, Barbui T, Rosing J, Cate HT, Falanga A. (2008). Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112, 4061–8.
   PubMed Web of Science ®Google Scholar
• Massberg S, Grahl L, von Bruehl ML, Mannukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, et al. (2010). Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16:887–96.
   PubMed Web of Science ®Google Scholar
• McMullin MF. (2009). Idiopathic erythrocytosis: a disappearing entity. Hematology 2009:629–35.
   Google Scholar
• Piccin A, Murphy WG, Smith OP. (2007). Circulating microparticles: pathophysiology and clinical implication. Blood Rev 21:157–71.
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, et al. (2007). JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 1356:444–5.
   Google Scholar
• Stuart MJ, Setty BN. (2001). Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Ped Pathol Mol Med 20:27–46.
   PubMed Web of Science ®Google Scholar
• Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. (1986). Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–51.
   PubMed Web of Science ®Google Scholar
• Verhoeven AJ, Hilarius PM, Dekkers DWC, Lagerberg JWM, de Korte D. (2006). Prolonged storage of red blood cells affects aminophospholipid translocase activity. Vox Sanguinis 91:244–51.
   PubMed Web of Science ®Google Scholar
• Wood BL, Gibson DF, Tait JF. (1996). Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow cytometric measurement and clinical association. Blood 88:1873–80.
   PubMed Web of Science ®Google Scholar
• Zaleskas VM, Krause DS, Lazarides K, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA. (2006). Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1:e18.
   PubMed Web of Science ®Google Scholar